U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Unknown
149124
Substance Class Protein
Created
by admin
on Mon Mar 31 20:55:59 GMT 2025
Edited
by admin
on Mon Mar 31 20:55:59 GMT 2025
Protein Type MONOCLONAL ANTIBODY
Protein Sub Type IGG2
Sequence Origin HUMANIZED MOUSE
Sequence Type COMPLETE
Record UNII
H18SKU3289
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
VISILIZUMAB
INN   USAN   WHO-DD  
USAN   INN  
Official Name English
visilizumab [INN]
Preferred Name English
VISILIZUMAB [USAN]
Common Name English
IMMUNOGLOBULIN G2 (HUMAN-MOUSE MONOCLONAL HUM291 .GAMMA.2-CHAIN ANTI-HUMAN ANTIGEN CD3), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL HUM291 .KAPPA.-CHAIN, DIMER
Common Name English
HUM-291
Code English
MAB HUMANIZED (IGG2) ANTI P09693 (CD3G_HUMAN) (HUM291)
Common Name English
NUVION
Brand Name English
HUM291
Code English
IMMUNOGLOBULIN G2 (HUMAN-MOUSE MONOCLONAL HUM291 .GAMMA.2-CHAIN ANTI-HUMAN ANTIGEN CD3), DISULPHIDE WITH HUMAN-MOUSE MONOCLONAL HUM291 .KAPPA.-CHAIN, DIMER
Common Name English
Visilizumab [WHO-DD]
Common Name English
MAB HUMANIZED TO CD3+ T CELLS
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C20401
Created by admin on Mon Mar 31 20:55:59 GMT 2025 , Edited by admin on Mon Mar 31 20:55:59 GMT 2025
Code System Code Type Description
FDA UNII
H18SKU3289
Created by admin on Mon Mar 31 20:55:59 GMT 2025 , Edited by admin on Mon Mar 31 20:55:59 GMT 2025
PRIMARY
USAN
KK-166
Created by admin on Mon Mar 31 20:55:59 GMT 2025 , Edited by admin on Mon Mar 31 20:55:59 GMT 2025
PRIMARY
SMS_ID
100000137406
Created by admin on Mon Mar 31 20:55:59 GMT 2025 , Edited by admin on Mon Mar 31 20:55:59 GMT 2025
PRIMARY
DRUG BANK
DB12053
Created by admin on Mon Mar 31 20:55:59 GMT 2025 , Edited by admin on Mon Mar 31 20:55:59 GMT 2025
PRIMARY
INN
8054
Created by admin on Mon Mar 31 20:55:59 GMT 2025 , Edited by admin on Mon Mar 31 20:55:59 GMT 2025
PRIMARY
ChEMBL
CHEMBL2108811
Created by admin on Mon Mar 31 20:55:59 GMT 2025 , Edited by admin on Mon Mar 31 20:55:59 GMT 2025
PRIMARY
WIKIPEDIA
VISILIZUMAB
Created by admin on Mon Mar 31 20:55:59 GMT 2025 , Edited by admin on Mon Mar 31 20:55:59 GMT 2025
PRIMARY
EVMPD
SUB75525
Created by admin on Mon Mar 31 20:55:59 GMT 2025 , Edited by admin on Mon Mar 31 20:55:59 GMT 2025
PRIMARY
CAS
219716-33-3
Created by admin on Mon Mar 31 20:55:59 GMT 2025 , Edited by admin on Mon Mar 31 20:55:59 GMT 2025
PRIMARY
NCI_THESAURUS
C2229
Created by admin on Mon Mar 31 20:55:59 GMT 2025 , Edited by admin on Mon Mar 31 20:55:59 GMT 2025
PRIMARY
From To
1_22 1_96
1_134 3_213
1_147 1_203
1_222 2_222
1_223 2_223
1_226 2_226
1_229 2_229
1_260 1_320
1_366 1_424
2_22 2_96
2_134 4_213
2_147 2_203
2_260 2_320
2_366 2_424
3_23 3_87
3_133 3_193
4_23 4_87
4_133 4_193
Glycosylation Type MAMMALIAN
Glycosylation Link Type Site
N 1_296
N 2_296
Related Record Type Details
T-CELL SURFACE GLYCOPROTEIN CD3 EPSILON CHAIN
TARGET -> INHIBITOR
Related Record Type Details
VISILIZUMAB
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
MOL_WEIGHT:NUMBER(CALCULATED) CHEMICAL
Molecular Formula CHEMICAL
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966